Invests for Blackstone Life Sciences, which he joined in May 2020; co-founded Praxis Precision Medicines in 2016 and ran it as CEO.
| Episode 48: Blackstone's Kiran Reddy | BioVenture VoiCes with Chris Garabedian | 2026-09-21 | Blackstone's Senior Managing Director Kiran Reddy describes his early life and education, and the impact that patient care has had on his approach to investing. He describes notable investments in neuroscience, and a stop at Biogen, before returning to investing at Clarus, which was acquired by Blackstone. He recalls the unique opportunity he saw when a company with the resources of Blackstone decided to go big into life sciences. |